Cite
HARVARD Citation
Ryerson, L. et al. (2018). 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program. Journal of neurology, neurosurgery and psychiatry. 89 (6), p. A29. [Online].